Abstracts tagged "Sjogren’s syndrome and rituximab"

Abstract Number: 740 • 2019 ACR/ARP Annual Meeting
Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease
Magdalena Benad ¹, Dirk Koschel ¹, Kristine Herrmann ¹, Kristin Wiefel ¹, Alexander Kleymann ¹ and Martin Aringer², ¹University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ²Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany
Background/Purpose: Interstitial lung disease (ILD) is a common and life-threatening organ manifestation of patients with various connective tissue diseases (CTDs), and with systemic sclerosis and…
Abstract Number: 637 • 2015 ACR/ARHP Annual Meeting
Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience
Francesco Ferro¹, Chiara Baldini¹, Nicoletta Luciano¹, Maurizio Mazzantini¹, Daniela Martini¹, Sara Galimberti², Valentina Donati³, Marta Mosca⁴ and Stefano Bombardieri¹, ¹Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ²Hematology Unit, University of Pisa, Italy, Pisa, Italy, ³Department of Pathology, AOUP, Pisa, Italy, Pisa, Italy, ⁴University of Pisa, Pisa, Italy
Background/Purpose: Recent insights from open studies and randomized clinical trials have shown the effectiveness of Rituximab (RTX) in controlling disease activity, patients’ subjective symptoms and…
Abstract Number: 2789 • 2015 ACR/ARHP Annual Meeting
Blood and Salivary Gland BAFF-Driven B-Cell Hyperactivity in Rituximab Non-Responder Patients with Primary Sjögren’s Syndrome
Divi Cornec¹, Sebastian Costa², Valerie Devauchelle³, Sandrine Jousse-Joulin⁴, Pascale Marcorelles⁵, Jean-Marie Berthelot⁶, laurent chiche⁷, Eric Hachulla⁸, Pierre-Yves Hatron⁹, Vincent Goeb¹⁰, O Vittecoq¹¹, Alain Saraux¹² and Jacques-Olivier Pers¹³, ¹Department of rheumatology, Brest Occidentale University, Brest, France, ²anatomopathological department, Brest university hospital, Brest, France, ³Service de Rhumatologie, CHU Brest, Brest, France, ⁴Rheumatology, CHu La cavle Blanche, Brest, France, ⁵anatomopathological department, Brest university hospital, CHU Morvan, Brest, France, ⁶Rhumatologie, CHU Nantes, Nantes, France, ⁷internal medicine, Hopital Europeen, Marseille, France, ⁸Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ⁹Service de Médecine Interne, Centre National de Référence des Maladies Systémiques Rares, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁰Rhumatologie, CHU Amiens, Amiens, France, ¹¹University Hospital, Rouen, France, ¹²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ¹³EA2216/ERI29 UBO, Brest, France
Background/Purpose: To determine whether B-cell markers (blood and minor salivary gland (SG) B-cell depletion (BCD), autoantibodies, BAFF) are associated with clinical response to rituximab in…
Abstract Number: 2554 • 2012 ACR/ARHP Annual Meeting
Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome: Final Results of a Randomized Controlled Trial
Valerie Devauchelle-Pensec¹, Xavier Mariette², Sandrine Jousse-Joulin³, Jean-Marie Berthelot⁴, Aleth Perdriger⁵, Eric Hachulla⁶, Xavier Puechal⁷, Véronique Le Guern⁸, Jean Sibilia⁹, Jacques-Eric Gottenberg¹⁰, Laurent Chiche Sr.¹¹, Vincent Goeb¹², Gilles Hayem¹³, Jacques Morel¹⁴, Charles Zarnitsky¹⁵, JJ Dubost¹⁶, Jacques-Olivier Pers¹⁷, Emmanuel Nowak¹⁸ and Alain Saraux¹⁹, ¹Department of rheumatology and unit of immunology (EA2216), Brest Occidentale university, Brest, France, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ³Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ⁴Rheumatology Unit, Nantes University Hospital, Nantes, France, ⁵Rheumatology, Hôpital Sud, Rennes, France, ⁶Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁷Internal Medicine, Hôpital Cochin, Paris, France, ⁸Department of Internal Medicine, Cochin Hospital, Paris, France, ⁹Université de Strasbourg, EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, ¹⁰Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Internal Medicine, CHU Marseille, Marseille, France, ¹²Rheumatology, Rouen University Hospital, Rouen, France, ¹³Rheumatology Unit, Bichat Hospital, Paris, France, ¹⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ¹⁵Rheumatology, CH du Havre, Le Havre, France, ¹⁶Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹⁷Unit of immunology, EA 2216, Brest Occidentale University, Brest, France, ¹⁸CIC, CHU Brest, Brest, France, ¹⁹Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France
Background/Purpose: There is evidence for a critical role of B cells in the pathogenesis of pSS. Both open labelled and small controlled studies suggested the…
Abstract Number: 1751 • 2012 ACR/ARHP Annual Meeting
Effect of Repeated Infusions of Rituximab in Patients with Primary Sjögren’s Syndrome
Maria Perez-Ferro¹, Sheila Recuero², Fredeswinda I. Romero¹, Cristina Serrano³, Maria J. Rodriguez-Nieto⁴, Julio Gomez-Seco², Teresa Presa², Javier R. Godo², Gabriel Herrero-Beaumont⁵ and Olga Sanchez-Pernaute², ¹Section for Autoimmune Diseases, Rheumatology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ²Jimenez Díaz Foundation University Hospital, Madrid, Spain, ³Immunology, Jiménez Díaz Foundation University Hospital, Madrid, Spain, ⁴Section for Autoimmune Diseases. Pneumology, Jimenez Díaz Foundation University Hospital, Madrid, Spain, ⁵Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz, Madrid, Spain
Background/Purpose: To assess the safety and efficacy of repeated infusions of rituximab (RTX) in patients with primary Sjögren syndrome (PSS). Methods: Patients with PSS were…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].